Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Billboard-charting Songwriter & Recording Artist OG Maco Signs with Pro Music Rights



Reading Time: 4 minutes

Privately-Funded For-Profit Public Performing Rights Organization
Welcomes Artist to Growing Roster of Music Stars

NAPLES, Fla.–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;$AAPLlt;/agt; lt;a href=”” target=”_blank”gt;#PMRlt;/agt;–Pro Music Rights, the groundbreaking performing rights organization
(PRO) that recently partnered with music technology company VNUE, Inc.
(OTC:VNUE) to require its Soundstr MRT (Music Recognition Technology)
for all of its licensees, is proud to announce the signing of
Billboard-charting recording artist and songwriter OG Maco.

OG Maco is best known for his 2014 debut single entitled “U Guessed It,”
a viral hit that peaked at number 90 on the US Billboard Hot 100 Charts.
OG Maco has collaborated with dozens of artists, including Migos, Diplo,
2 Chainz, Gucci Mane, Waka Flocka Flame, Offset, Fallout Boy, and many

“I’m overjoyed that OG Maco has chosen to bring his catalog to the Pro
Music Rights family,” Pro Music Rights Founder and CEO Jake P. Noch said
in a statement. “He is a standout star in our sterling—and
rapidly-expanding—roster of some of the world’s greatest musical


Pro Music Rights is a privately-funded, for-profit performing rights
organization, only the fifth-ever organization of its kind formed in the
United States. The organization was started by Jake P. Noch –
Entrepreneur, Music Industry Executive, and Musician – in 2018. In that
short amount of time, Pro Music Rights has already secured a market
share of 7.4% in the USA and represents thousands of artist brands
throughout the industry. Pro Music Rights repertoire includes works that
feature such notable acts as Snoop Dog, A$AP Rocky, Wiz Khalifa,
Pharrell, Young Jeezy, Julez Santana, Lil’ Yachty, the late Nipsey
Hussle & Countless more. VNUE’s Soundstr technology will track and audit
music plays, so that the correct rights holders are compensated.

VNUE, Inc. CEO Zach Bair said, “With the addition of OG Maco to Pro
Music Rights’ roster, the industry should take note that artists will no
longer have to stand idle while their royalties are tied up in an
opaque, antiquated system, where no one, particularly the songwriters
and artists, really knows where that money goes or if they are being
paid their due. I am excited to work with Jake, and for VNUE to provide
the underlying technology in helping to shape this new and innovative
model, one which we believe will be the future of general music

“Over my years in the industry, I’ve seen and experienced all the
systematic issues caused by other Performing Rights Organizations that
drag the creative industry down as a whole,” continued Noch. “They
hinder the livelihoods of the entire creative community. The Pro Music
Rights model, which leverages VNUE’s Soundstr Music Recognition
Technology ( to create a true ‘pay-per-play’ system, aims
to disrupt the old way of doing things and will create a better world
for musical artists & music publishers everywhere.”

OG Maco says he “is so happy to finally be able to advance my career
with a company and a CEO I’d trust not only with my wallet but with my
life,” speaking about Pro Music Rights and Jake Noch. He adds, “Pro
Music Rights is the future of artists rights and the perfect way to meld
the interests of the artists and the acumen of a Fortune 500 company.”

With the Pro Music Rights model, 100% of all public performance
royalties are paid directly to the performers, songwriters, publishers,
and legally-entitled rights holders—like OG Maco—who get paid on a
monthly basis—all without having administrative fees deducted from their
public performance royalties. The extensive Pro Music Rights catalog
represents over 2,200,000+ works.


Pro Music Rights is actively reaching out to major DSPs such as Apple
(Nasdaq:AAPL), Google (Nasdaq:GOOGL), Amazon (Nasdaq:AMZN), Spotify
(NYSE:SPOT), Facebook (NASDAQ:FB), 7Digital (LON:7DIG), Tencent
more, to reach licensing agreements for Pro Music Rights catalog music
played on each service through its Global IP Counsel Richard
Gora, Esq.
of Gora
All agreements will require Soundstr monitoring and auditing.

About Pro Music Rights, LLC. (

Pro Music Rights is the 5th ever formed public performance rights
organization (PRO) in the United States, that controls a market share of
7.4% in the USA and that represents over 2,000,000 works, some that
feature such notable acts as some as Snoop Dogg, A$AP Rocky, Wiz
Khalifa, Pharrell, Young Jeezy, the late Nipsey Hussle, and many others.
Pro Music Rights pays 100% of all public performance royalties directly
to the performers, songwriters, publishers, and legally entitled rights
holders who have joined Pro Music Rights on a monthly basis. Jake P.
Noch founded Pro Music Rights in January of 2018 and serves as the
company’s CEO after experiencing firsthand the systematic issues that
plague the field of public performance rights, and hinders the
livelihood of performers, songwriters, publishers, and the creative
community as a whole. For more information, please visit (

About VNUE, Inc. / Soundstr (

VNUE, Inc., (OTC: VNUE) is dedicated to further monetizing the live
music experience for artists, labels, writers, and publishers, by
bringing together technology such as its (
platform, exclusive license partner and “instant live” pioneer DiscLive (,
and music recognition technology (MRT) Soundstr (,
which helps businesses pay fairer music license fees based on actual
music usage. The veteran entrepreneurs, artists and songwriters
behind VNUE are passionate about the future of their industry and
ensuring that rights holders’ value is not lost amid always-changing
technology. VNUE’s team led by CEO Zach Bair, known as the pioneer in
“instant live” recording, has produced live content and created
experiential products for over 15 years for artists and companies
including Slash, Seether, Peter Frampton, Foreigner, The Pixies,
Blondie, EMI, Capitol Records, Rob Thomas, Bad Company, REO Speedwagon,
Devo, and many more. In addition to Bair, the company’s leadership team
also includes Lou Mann, former GM of Capitol Records and former
president of House of Blues Media Properties; Jock Weaver, former
president of Hard Rock International, founder and former president of
TBA Entertainment, and chairman of Heritage Trust Company (a private
equity firm); Jim King, former EVP at BMI, and who held “C” level
positions at other major companies; Tony “Montana” Cardenas, founder of
DiskFaktory and a platinum-selling Capitol Records recording artist and
writer formerly with the band Great White; and Jeff Zakim, former head
of Digital for Blue Note Records, and Global Digital Strategy for EMI



For Pro Music Rights
Jake Noch
Investor Relations / [email protected]

For VNUE, Inc.
Investor Relations / [email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493


Rodedawg (OTC: RWGI) Launches TikTok Shop to Expand into Global E-Commerce Market



Continue Reading


Industrial Hemp Market Soars from $6.6 Billion to $25.7 Billion by 2034, Fueled by Sustainable Innovation




Industrial Hemp Playing Key Role in Carbon Sequestration and Soil Remediation Aligning with Sustainable Farming Practices

ROCKVILLE, Md., June 12, 2024 /PRNewswire/ — Based on a new research report by Fact.MR, worldwide sales of Industrial Hemp Market are estimated to reach US$ 6.6 billion in 2024. By 2034, this market is anticipated to skyrocket to a staggering US$ 25.7 billion, driven by a steady CAGR of 14.5% from 2024 onward.

Demand for industrial hemp is skyrocketing as more and more industries recognize its versatile and sustainable properties. Once overlooked, this remarkable crop is now being embraced for its myriad uses across various sectors. From textiles and construction materials to biofuels and nutritional supplements, hemp’s applications are seemingly endless.

Environmentally conscious consumers are driving much of this demand, as hemp requires minimal pesticides and herbicides, making it an eco-friendly choice for sustainable farming. Its ability to sequester carbon dioxide and remediate contaminated soil further adds to its appeal. Moreover, hemp’s durability, lightweight nature, and renewable qualities make it an attractive alternative to traditional materials in manufacturing.

Request a Sample of this Report:


As awareness of hemp’s benefits continues to spread, industries are investing in research and development to unlock its full potential. With its multi-faceted applications and sustainable credentials, industrial hemp is poised to become a cornerstone of the green economy, meeting the growing demand for environmentally responsible products and practices.

Key Takeaways from the Market Study:

  • Based on nature, sales of organic hemp are estimated to reach a valuation of $3.2 billion in 2024.
  • The market in Mexico is evaluated to expand at a CAGR of 13.6% from 2024 to 2034.
  • Revenue from sales of industrial hemp in East Asia is projected to reach $5.9 billion by the end of 2034.
  • The South Korean market is evaluated to reach a valuation of $1.4 billion by the end of 2034.
  • North America is analyzed to hold a global market share of 24.3% by 2034.

“Use of industrial hemp in textiles, medicines, and food, coupled with global sustainability trends, is creating opportunities for suppliers. Governments worldwide are collaborating to boost global hemp distribution,” says a Fact.MR analyst.

Increasing Awareness of Therapeutic Potential of Hemp in Medical Applications

Once relegated to the fringes, industrial hemp is rapidly emerging as a sustainable wonder crop, fueling a wave of cutting-edge innovations across diverse industries. As researchers and entrepreneurs unlock its vast potential, hemp is proving to be a versatile and eco-friendly resource, paving the way for exciting new products and applications.

The automotive industry is also exploring the use of hemp fibers as a reinforcement material for lighter, stronger, and more sustainable car parts. These natural fiber composites could reduce vehicle weight, improving fuel efficiency and reducing emissions.


In the field of biotechnology, scientists are harnessing the unique properties of hemp to develop innovative products. For instance, researchers are exploring the use of hemp-derived compounds, such as cannabidiol (CBD), for their potential therapeutic applications in various medical conditions.

Japan’s Industrial Hemp Market Poised for Rapid Growth

The industrial hemp market in Japan is projected to grow at a compound annual growth rate (CAGR) of 15.1% from 2024 to 2034, with the country expected to hold a 29.4% market share by the end of the period.

Increased investment in research is crucial for unlocking the full potential of industrial hemp. Research efforts may focus on improving hemp genetics for higher yield and quality, optimizing cultivation practices, and exploring innovative applications such as advanced nanomaterials or pharmaceuticals. This investment fosters innovation and establishes a foundation for the hemp industry’s long-term growth and competitiveness in an ever-evolving market.

Get Customization on this Report for Specific Research Solutions:


Expanding Opportunities in the United States Industrial Hemp Market

The industrial hemp market in the United States offers abundant opportunities for stakeholders to broaden their product portfolios. Beyond traditional uses like textiles and oils, there is significant potential for hemp-based products to evolve into biodegradable polymers, eco-friendly packaging, and even biofuels. This diversification, a prominent trend in the industrial hemp market, not only targets emerging markets but also positions hemp as a versatile and sustainable resource with applications across various industries.

More Valuable Insights on Offer:

Fact.MR, in its new offering, presents an unbiased analysis of the industrial hemp market for 2019 to 2023 and forecast statistics for 2024 to 2034.

The study divulges essential insights into the market based on nature (organic, conventional), product type (fiber, seeds), and end use (food & beverages, consumer textiles, personal products, industrial applications, hemp CBD, supplements, other consumer products), across seven major regions of the world (North America, Latin America, Eastern Europe, Western Europe, East Asia, South Asia & Pacific, and MEA).


Check out More Related Studies Published by Fact.MR Research:

Hemp-Based Products Market is expected to reach $1.8 billion in 2023 and jump to a size of $16.2 billion by 2033.

Cannabis Infused Drinks Market is predicted to race ahead and end up at US$ 8.7 billion by 2032.

Ready-to-use Therapeutic Food Market to surge from $459.9M in 2024 to $800.6M by 2034, driven by 5.7% CAGR, marking substantial growth.

Specialty Fat and Oil Market will hit $85.94 billion by 2034 with a 4.6% Annual Growth Rate.


Baking Ingredient Market is set to reach $41.48 billion by 2034, Driven by 6.5% Annual Growth Rate.

Infant Milk Formula Market: From Growth Spurts to Baby Boom – Projected Surge to $22.35 Billion by 2034.

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape. 


11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team[email protected]
Follow Us: LinkedIn | Twitter | Blog


View original content:–fueled-by-sustainable-innovation-302170602.html

Continue Reading


Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs




HERZLIYA, Israel and CALGARY, AB, June 11, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the success and conclusion of a preliminary safety evaluation of Innocan’s single injection and sustained-release LPT-CBD conducted on minipigs. The animals demonstrated excellent drug tolerance and did not exhibit any drug-related adverse events.



Recognized by the FDA as an excellent model for toxicology, small breeds of miniature domestic pigs known as minipigs share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms. In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month. Encouragingly, the animals all exhibited good drug tolerance and did not manifest any drug-related adverse reactions.

“We are thrilled with these findings, which further underpin the safety profile of LPT-CBD following a single injection,” commented Dr. Eyal Kalo, the R&D Director of Innocan Pharma. “With each new data point collected for LPT-CBD, we make significant strides in our quest to revolutionize patient care through sustained-release therapy. Our efforts to continuously gather data to fully characterize LPT-CBD are paramount in our journey towards its ultimate approval.”


Professor Chezy Barenholz the CSO of Innocan Pharma added, “These results are immensely gratifying and hold significant promise as they highlight the characteristics of LPT-CBD in a physiological setting similar to humans.”

The study involved administering three ascending doses of LPT-CBD via subcutaneous injection in minipigs, followed by comprehensive monitoring of pharmacokinetics and safety parameters for 28 days. Throughout the study, the minipigs demonstrated excellent drug tolerance, as evidenced by blood clinical parameters whithin normal range, healthy appetite, and normal behavior. These findings are consistent with prior safety evaluations conducted with LPT-CBD on diverse animal models including goats and dogs, affirming the drug’s favorable tolerability profile following both single and repeated use.

Grant of Restricted Share Units                                                                                                 

The Company has granted an aggregate of 290,000 restricted share units (each, an “RSU“) to consultants. Each RSU entitles the recipient to receive one common share of the Company (a “Common Share“) on vesting. A total of 150,000 RSUs vest on May 30, 2024, and 140,000 RSUs vest on September 30, 2024. The RSUs and the underlying Common Shares are subject to a statutory hold period of four months and one day expiring on October 1, 2024.

Innocan also announces that it granted 2,380,000 stock options to employees and consultants to the Company. These options have a strike price of $0.28, with various vesting periods up to 12 months. All options expire on May 30, 2029.


About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales.

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
[email protected] 



Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.



Cision View original content:

Continue Reading

Latest news

Trending on Grassnews Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania